[Pembrolizumab+chemotherapy as first-line treatment in patients with HER2 negative advanced oesogastric adenocarcinoma]

Martin Duval; Aziz Zaanan

doi:10.1016/j.bulcan.2024.01.004

[Pembrolizumab+chemotherapy as first-line treatment in patients with HER2 negative advanced oesogastric adenocarcinoma]

Bull Cancer. 2024 May;111(5):431-432. doi: 10.1016/j.bulcan.2024.01.004. Epub 2024 Mar 7.

[Article in French]

Authors

Martin Duval¹, Aziz Zaanan²

Affiliations

¹ Service d'oncologie médicale, institut Curie, hôpital René-Huguenin-Saint-Cloud, 35, rue Dailly, 92210 Saint-Cloud, France. Electronic address: martin.duval@aphp.fr.
² Département d'oncologie digestive, hôpital européen Georges-Pompidou (HEGP), Assistance publique-Hôpitaux de Paris (AP-HP), université Paris Cité, institut du cancer parisien CARPEM, 20, rue Leblanc 75015 Paris, France.

PMID: 38458924
DOI: 10.1016/j.bulcan.2024.01.004

No abstract available

Keywords: Adénocarcinome de la jonction œsogastrique; Adénocarcinome gastrique; First-line treatment; Gastric adenocarcinoma; Gastro-esophageal junction adenocarcinoma; Immunotherapy; Immunothérapie; Maladie métastatique; Metastatic disease; Première ligne.

Publication types

Letter

MeSH terms

Adenocarcinoma* / drug therapy
Adenocarcinoma* / pathology
Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Esophagogastric Junction / pathology
Humans
Receptor, ErbB-2* / metabolism
Stomach Neoplasms* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Receptor, ErbB-2
pembrolizumab
Antineoplastic Agents, Immunological
ERBB2 protein, human